Our Work
Latham & Watkins Advises on Abeona Therapeutics’ US$30 Million Private Placement
November 9, 2026
Firm represents the placement agent in the PIPE by the commercial-stage biopharmaceutical company.
Abeona Therapeutics Inc. (Nasdaq: ABEO) has announced it has entered into a securities purchase agreement with a group of investors for a private placement of 6.4 million shares of common stock at a purchase price of US$3.75 per share and pre-funded warrants to purchase up to 1,600,043 shares of common stock at a purchase price of US$3.7499 per pre-funded warrant, expected to result in US$30 million in gross proceeds before fees and expenses.
Latham & Watkins LLP represents the placement agent in the transaction with a Capital Markets team led by San Diego partner Matt Bush and counsel Anthony Gostanian, with associates Omeed Valipour and Katie Raya.